Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

lenovo联想

Lenovo Group Limited 聯想集團有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 0992)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of the Company announces that Dr. Wu Yibing has been appointed as a non-executive director of the Company with effect from May 21, 2009.

The board of directors (the "Board") of Lenovo Group Limited (the "Company") is pleased to announce the appointment of Dr. Wu Yibing as a non-executive director of the Company with effect from May 21, 2009.

Dr. Wu, aged 41, received a Ph.D. from Harvard University and a B.Sc. from the University of Science and Technology of China. He is the Managing Director and Executive Vice President of Legend Holdings Limited ("Legend Holdings"), the controlling shareholder of the Company.

Before joining Legend Holdings, he was the chief transformation officer of the Company and was responsible for designing and implementing process and organizational changes and overseeing key strategic initiatives.

From 1996 to 2008, Dr. Wu was a senior partner, general manager of Beijing office and head of Asia-Pacific Post-Merger Management Practice of McKinsey & Company ("McKinsey"). He has served clients in China, across Asia-Pacific, and in the U.S. from a wide range of industries including high tech, telecom, health care, energy, and financial services. Before joining McKinsey, Dr. Wu worked as a technology licensing consultant at Harvard University.

Save as disclosed above, Dr. Wu has not held any directorship with any listed company in the last three years. He does not have any relationship with any director, senior management or substantial shareholder or controlling shareholder of the Company nor any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Dr. Wu currently does not hold any position with the Company or any of the Company's group of companies other than that of a non-executive director of the Company.

The length of service of Dr. Wu with the Company will be subject to retirement by rotation and re-election at annual general meeting of the Company in accordance with the Articles of Association. Dr. Wu will be paid aggregate fees and remuneration of US\$180,000 per annum which comprise of cash director's fees of US\$60,000 and equity rights with a value of US\$120,000. In determining the amount of the director's fees and remuneration to be paid to Dr. Wu, the Board has taken into account the level of remuneration paid to non-executive directors of comparable companies, the amount of time that Dr. Wu will be required to commit in fulfilling his duties as a non-executive director, the amount paid to existing non-executive directors of the Company, and the recommendation of the Compensation Committee of the Board.

Save as disclosed herein, there is no other matter that needs to be brought to the attention of the shareholders of the Company in relation to the above appointment and there is no information to be disclosed pursuant to Rule 13.51(2) of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend a warm welcome to Dr. Wu in joining the Company.

By order of the Board
Liu Chuanzhi
Chairman

Hong Kong, May 21, 2009

As at the date hereof, the executive director is Mr. Yang Yuanqing; the non-executive directors are Mr. Liu Chuanzhi, Mr. Zhu Linan, Ms. Ma Xuezheng, Mr. James G. Coulter, Mr. William O. Grabe, Dr. Wu Yibing and Mr. Justin T. Chang (alternate director to Mr. James G. Coulter); and the independent non-executive directors are Professor Woo Chia-Wei, Mr. Ting Lee Sen, Mr. John W. Barter III and Dr. Tian Suning.